A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Inclusion Criteria: Stage A: Patient: * aged \> 18 years. * with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors. * with asymptomatic disease in progression detected by increase of CA 125 levels according to GCIG criteria during systematic follow-up, with or without measurable lesions. * with disease in progression \> 6 months after a first or second line including a platinum derivative. Patients should have received previously a taxane derivative. * Adequate bone marrow, renal and hepatic function defined as: . WBC \> 3.0 x 109/L or Neutrophils (ANC) \> 1,5 x 109/L; Platelets \> 100 x 109/L; Hemoglobin \> 6 mmol/L (10,0 mg/dL); Bilirubin \< 2 x upper normal limit of normal range; Estimated glomerular filtration rate \> 50 ml/mn according to Cockroft-Gault formula. * with ECOG performance status = 0 or 1. * with a life expectancy of at least 16 weeks * who have given their signed and written informed consent to participate in the trial after fully understanding the implication and constraints of the protocol. Stage B: Patients * aged \> 18 years. * with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors. * with disease in progression \> 6 months after a first or second line including a platinum derivative. patients should have received previously a taxane derivative. * Measurable disease by RECIST or evaluable disease by GCIG (CA-125). * Patients included in stage A with disease in progression under lenalidomide could be eligible in phase B if they did not experience unacceptable toxicity under lenalidomide in stage A. Patients should stop lenalidomide for 7 days before entry in stage B (7 days wash out). * Adequate bone marrow, renal and hepatic function defined as: . WBC \> 3.0 x 109/L or Neutrophils (ANC) \> 1,5 x 109/L; Platelets \> 100 x 109/L; Hemoglobin \> 6 mmol/L (10,0 mg/dL); Bilirubin \< 2 x upper normal limit of normal range; Estimated glomerular filtration rate \> 50 ml/mn according to Cockroft-Gault formula. * with LVEF under normal range * with ECOG performance status = 0 or 1. * with a life expectancy of at least 16 weeks. * who have given their signed and written informed consent to participate in the trial after fully understanding the implication and constraints of the protocol. Exclusion Criteria: * Ovarian tumors of low malignant potential (borderline tumors). * Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Mullerian tumors). * Patients with a prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin). * Patients who have received previous radiotherapy. * Presence of symptomatic brain metastases. * Patients with a history of seizure disorder or central nervous system disorders; pre-existing motor or sensory neurologic pathology or symptoms \> NCI-CTC grade 1. * History of congestive heart failure (NYHA Classification \> 2, even if medically controlled. History of clinical and electrocardiographically documented myocardial infarction within the last 6 months. History of atrial or ventricular arrhythmias (≥ LOWN II). * Thrombosis or anti-thrombosis treatment within 6 months. * History of visceral bleeding, gastrointestinal ulcer in 6 months. * Obstructive or sub-occlusive disease. * Patients with severe active infection. * Concurrent severe medical problems unrelated to malignancy which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy. * Fertile women not using adequate contraceptive methods, or who are pregnant or breast feeding. * Histories of allergy or sentimentality known about the similar chemical compounds in the carboplatine, either in the doxorubicine liposomale pégylée, or in one of the constituents of the lenalidomide. * Patient having developed a knotty erythema characterized by a rash with desquamation during grip(taking) of thalidomide or a medicine similaire. * Previous administration of lenalidomide. * Seropositivity known about the virus of the human immunodeficiency (HIV), or pathology bound to the syndrome of acquired immunodeficiency (AIDS) or hepatitis activates type A, B or C. * Administration of other simultaneous chemotherapeutic drugs, or hormonal therapy, or simultaneous radiotherapy during the study treatment period (hormone replacement therapy is allowed as are steroid antiemetics). * Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent.